Vedolizumab for Primary Sclerosing Cholangitis (with IBD)?

“The monoclonal antibody vedolizumab may reduce biliary inflammation in patients with primary sclerosing cholangitis and comorbid inflammatory bowel disease, according to early, open-label study findings reported at the meeting sponsored by the European Association for the Study of the Liver”  –according to GIHepNews: Biliary inflammation reduced by IBD drug

“Vedolizumab given to 27 patients with primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) resulted in a 50% reduction or normalization of serum alkaline phosphatase levels in 17 cases (63%).”

This was an open-label, proof-of-concept study involving 27 patients aged 25-30 years with PSC and comorbid IBD.

My take: This is interesting but needs a lot more study.

Atlanta Zoo 2016

Atlanta Zoo 2016

4 thoughts on “Vedolizumab for Primary Sclerosing Cholangitis (with IBD)?

  1. Pingback: Primary Sclerosing Cholangitis 2016 | gutsandgrowth

  2. Pingback: Should We Care About Subclinical Primary Sclerosing Cholangitis with Inflammatory Bowel Disease? | gutsandgrowth

  3. Pingback: Liver Problems with Inflammatory Bowel Disease | gutsandgrowth

  4. Pingback: Ursodeoxycholic Acid in Pediatric Primary Sclerosing Cholangitis | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.